AGP Picks
View all

Connecticut Health Digest: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Connecticut Health Digest.

Press releases published on November 18, 2026

Charter Oak State College Hosts Virtual Graduate Open House December 9
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Increased Dose of 15 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study
Adaptive Biotechnologies Highlights clonoSEQ’s Central Role in Advancing MRD-Guided Care Across Hematology at ASH 2026
Olema Oncology Presents Preclinical Data on Selective KAT6A Degraders in ER+/HER2- Breast Cancer Models at EORTC-NCI-AACR Symposium
Nyxoah Obtains Default Decision Against Inspire Medical Systems in Unified Patent Court Case
Nyxoah Obtient une Décision par Défaut contre Inspire Medical Systems dans une Procédure devant l’Unified Patent Court
Novo Nordisk Foundation commits US$60 million to strengthen CARB-X efforts against antimicrobial resistance
Zealand Pharma announces initiation of the Phase 2 ZYNERGY trial of petrelintide co-administered with enicepatide in people with obesity or overweight
Medline Inc. announces pricing of secondary offering of Class A common stock
SELLAS anuncia resultados positivos del ensayo pivotal de fase 3 REGAL, que demuestran que la vacuna inmunoterapéutica contra el cáncer galinpepimut-S (GPS) produjo una mejora estadísticamente significativa y clínicamente relevante de la supervivencia …
SELLAS Life Sciences Divulga Dados Positivos do Estudo REGAL Pivotal de Fase 3, Indicando que Galinpepimut-S (GPS), a Vacina Imunoterapêutica Contra o Câncer, Demonstrou uma Melhora Estatisticamente Significativa e Clinicamente Relevante na Sobrevida…

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Connecticut Health Digest

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.